Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

947 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.
Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL; Childhood Myositis Heterogeneity Study Group. Kishi T, et al. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1088-1094. doi: 10.1002/acr.23113. Arthritis Care Res (Hoboken). 2017. PMID: 28129483 Free PMC article.
Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features.
Sherman MA, Graf R, Sabbagh SE, Galindo-Feria AS, Pinal-Fernandez I, Pak K, Kishi T, Flegel WA, Targoff IN, Miller FW, Lundberg IE, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Among authors: kishi t. Rheumatology (Oxford). 2023 Feb 23;62(SI2):SI226-SI234. doi: 10.1093/rheumatology/keac428. Rheumatology (Oxford). 2023. PMID: 35961028 Free PMC article.
Medications received by patients with juvenile dermatomyositis.
Kishi T, Bayat N, Ward MM, Huber AM, Wu L, Mamyrova G, Targoff IN, Warren-Hicks WJ, Miller FW, Rider LG; Childhood Myositis Heterogeneity Study Group. Kishi T, et al. Semin Arthritis Rheum. 2018 Dec;48(3):513-522. doi: 10.1016/j.semarthrit.2018.03.016. Epub 2018 Mar 28. Semin Arthritis Rheum. 2018. PMID: 29773230 Free PMC article.
Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.
Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Sabbagh S, et al. Among authors: kishi t. Ann Rheum Dis. 2019 Jul;78(7):988-995. doi: 10.1136/annrheumdis-2018-215004. Epub 2019 Apr 24. Ann Rheum Dis. 2019. PMID: 31018961 Free PMC article.
Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study.
Yamasaki Y, Kobayashi N, Akioka S, Yamazaki K, Takezaki S, Nakaseko H, Ohara A, Nishimura K, Nishida Y, Sato S, Kishi T, Hashimoto M, Mori M, Okazaki Y, Kuwana M, Ohta A. Yamasaki Y, et al. Among authors: kishi t. Rheumatology (Oxford). 2021 Oct 2;60(10):4821-4831. doi: 10.1093/rheumatology/keab108. Rheumatology (Oxford). 2021. PMID: 33576399
947 results